Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

statens serum institut, denmark artillerivej 5,, dk-2300 copenhagen s 45 32 68 32 68 - mycobacterium bovis (bcg) danish strain 1331 - ps.inj.sus (ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 2-8x10 6 cfu/ml - mycobacterium bovis (bcg) danish strain 1331 - tuberculosis, live attenuated

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

aj vaccines a/s, denmark artillerivej 5, dk-2300 copenhagen s +45 7229 7000 - mycobacterium bovis (bcg) danish strain 1331 - ps.inj.sus (ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 2-8x10 6 cfu/ml - mycobacterium bovis (bcg) danish strain 1331 0ml - tuberculosis, live attenuated

Կիպրոս - հունարեն - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - diphtheria toxoid; tetanus toxoid; bordetella pertussis antigens toxoid; bordetella pertussis antigens filamentous haemagglutinin; formalinavd\dat poliovirus typ 1 (stam brunenders); formalinavd\dat poliovirus typ 2 (stam mef1); formalinavd\dat poliovirus typ 3 (stam saukett) - suspension for injection in pre-filled syringe - diphtheria toxoid (8000000804) 30iu; tetanus toxoid (8000040440) 40iu; bordetella pertussis antigens toxoid (8000002964) 25ug; bordetella pertussis antigens filamentous haemagglutinin (8000003163) 25ug; formalinavd\dat poliovirus typ 1 (stam brunenders) (8000037458) 40du; formalinavd\dat poliovirus typ 2 (stam mef1) (8000037469) 8du; formalinavd\dat poliovirus typ 3 (stam saukett) (8000037470) 32du - diphtheria-pertussis-poliomyelitis-tetanus

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Αντινεοπλασματικοί παράγοντες - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - Λοιμώξεις αναπνευστικού συνκυτιακού ιού - Εμβόλια - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. Βλ. Ενότητες 4. 2 και 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

biotest pharma gmbh, germany landsteinerstraße 5, 63303 dreieich +49(0) 6103 801-0 - immunoglobulin human normal - sol.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ) - 50mg/ml - immunoglobulin human normal 50mg - immunoglobulins, normal human, for intravascular adm.

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

merck sharp & dohme ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΜΟΝΟΠΡΟΣΩΠΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΙΑ Δ.Τ. msd ΑΦΒΕΕ Αγ. Δημητρίου 63,, 174 56 174 56, Αλιμος 210.9897372 - hepatitis a, virus, purified inactivated - inj.susp (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 25 u/0,5ml(1ΔΟΣΗ) - hepatitis a, virus, purified inactivated 25u - hepatitis a, inactivated, whole virus

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

biotest pharma gmbh, germany landsteinerstraße 5, 63303 dreieich +49(0) 6103 801-0 - immunoglobulin human normal - sol.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ) - 100mg/ml - immunoglobulin human normal 100mg - immunoglobulins, normal human, for intravascular adm.

Կիպրոս - հունարեն - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

biotest pharma gmbh (0000003549) landsteinerstr. 5, dreieich, d-63303 - human plasmaprotein - solution for infusion - 100g/l - human plasmaprotein (8000028333) 100mg - immunoglobulins, normal human, for intravasc. adm.